Makary is recruiting researchers to weigh in on hormone therapy and SSRIs. The panels seem to have a bias, and the FDA’s goal is unclear.
Critics say the administration's approach, which it says is aimed at ending homelessness, lacks sufficient evidence to be expanded.
Regulatory decisions elsewhere mean the Sarepta drug, Elevidys, is not being shipped anywhere worldwide.
Alternatives to animal testing promise to transform basic research and hasten drug development. But what about study areas with no viable substitutes?
New Medicaid state directed payments will mostly benefit hospitals and medical providers in New Mexico and West Virginia
Regulators had initially said the drug should be rejected, but issued a limited approval recommendation following an appeal.
The president's order offers his clearest stance yet against harm reduction and is a significant escalation of his rhetoric on substance use
The fortunes of hospitals and health insurers are diverging, as the costs of care rise. But challenges loom for the entire industry.
